Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)

The summary for the Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional): Develop and test a prototype mobile/tablet technology-based application suitable for U.S. primary care settings, to serve as a low-cost user-friendly tool that primary care providers (PCPs) may use to deliver timely tailored feedback to patients following up on interventions for risky substance use. The feedback delivered should make sure patients engage in appropriate self-monitoring and self-management skills in adherence to treatment plans delivered during interventions for problematic substance use. Patients answers should inform delivery of tailored feedback (matching level of problematic substance-use risk as determined by validated screening and assessment tools) supporting health-promotion behaviors, such as helping patients adhere to evidence-based motivational interviewing or other behavioral therapy principles. The application also should track health action items completed, such as linkage to indicated follow-up treatment. It should be designed with a specific aim of improving coordination and delivery of indicated services to primary care patients at risk of developing substance use disorders (SUD).

Federal Grant Title:	Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-19-022
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 19th, 2019
Original Application Deadline:	March 19th, 2019
Posted Date:	January 9th, 2019
Creation Date:	January 9th, 2019
Archive Date:	April 24th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 9th, 2019

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See the funding announcement for the eligibility details
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-022.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...